CSTC 1

Drug Profile

CSTC 1

Alternative Names: BAC; CSTC1

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Charsire Biotechnology Corporation
  • Class Antidementias; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Diabetic foot ulcer; Vascular dementia

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Alzheimer's disease in USA (Topical) (NCT02886494)
  • 01 Dec 2016 Phase-II clinical trials in Vascular dementia in USA (Topical) (NCT02886494)
  • 31 Aug 2016 Charsire plans a phase II trial for Alzheimer's disease and Dementia in Taiwan (NCT02886494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top